Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement.

The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches.

By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.

Biotechnology

Life Sciences

Therapeutics

Attovia Therapeutics

Tao Fu

Senior/executive Director, Head Of Regulatory Affairs

Hubert Chen

Veit Schmelmer

Zaneta Odrowaz

Petter Veiby

Luisa Salter - Cid

Hangjun Zhan

David King

The Executive Management team at Attovia Therapeutics is responsible for directing the company's strategic vision and operational execution in the development of innovative biotherapeutics. They oversee research and development, ensure alignment between scientific goals and business objectives, and foster collaboration across departments. Additionally, they engage with stakeholders and drive initiatives that leverage the unique capabilities of the ATTOBODY platform to maximize the impact of therapies targeting immune-mediated diseases and oncology.

Executive Management

Leadership Team

Research and Development

Executive Management

About

Team members

Other teams at Attovia Therapeutics

Leadership Team

Research and Development